Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade |
---|---|
Source | CAS 853426-35-4 |
Species | Mus musculus |
Expression system | Mammalian cells |
Molecular weight | 54.1kDa |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Blinatumomab,AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3,CD19, CD3E,anti-CD19, CD3E |
Reference | PX-TA1067 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | (scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag |
Clonality | Monoclonal Antibody |
Blinatumomab is a monoclonal antibody constructed by BiTE (bispecific T cell engagers), which is used to treat relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) with negative Philadelphia chromosome. Blinatumomab is available as a drug under the Blincyto™ brand.
Blinatumomab Biosimilar - Anti-CD19, CD3E mAb, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Reviews
Il n’y a pas encore d’avis.